You are here

  • Home
  • Archive
  • Volume 65, Issue Suppl 1
  • PTH-084 Cost-Effectiveness of Vedolizumab Compared with Infliximab, Adalimumab, and Golimumab for Treatment of Moderately-to-Severely Active Ulcerative Colitis in The United Kingdom

Article metrics

Article menu
Download PDFPDF
BSG 2016
PTH-084 Cost-Effectiveness of Vedolizumab Compared with Infliximab, Adalimumab, and Golimumab for Treatment of Moderately-to-Severely Active Ulcerative Colitis in The United Kingdom

 

Online download statistics by month:

Online download statistics by month: August 2016 to March 2024

AbstractFullPdf
Aug 2016300
Sep 2016500
Oct 2016901
Nov 201626013
Dec 20162201
Jan 20172902
Feb 20171102
Mar 20171001
Apr 2017501
May 2017600
Jun 20171802
Jul 20171200
Aug 20173000
Sep 20173202
Oct 20171400
Nov 20173600
Dec 20173201
Jan 20183400
Feb 20181900
Mar 20181200
Apr 20182801
May 20181600
Jun 20183002
Jul 20181401
Aug 20181001
Sep 20181000
Oct 2018800
Nov 2018600
Dec 2018600
Feb 2019400
Mar 2019400
Apr 2019800
May 20191001
Jun 2019400
Jul 2019200
Aug 20191800
Sep 20191000
Oct 20194603
Nov 20192401
Dec 20191000
Jan 20202200
Feb 20201404
Mar 2020200
Apr 2020600
May 20201200
Jun 20202400
Jul 2020700
Aug 2020800
Sep 20203200
Oct 2020600
Nov 20201000
Dec 20201601
Jan 20211101
Feb 2021801
Mar 20211400
Apr 2021400
May 2021500
Jul 2021001
Oct 2021600
Nov 20211400
Dec 2021500
Jan 2022800
Feb 20221000
Mar 2022400
Apr 20221000
May 2022900
Jun 2022700
Jul 20221202
Aug 2022800
Sep 2022400
Oct 20221000
Nov 2022400
Dec 20221200
Jan 20237403
Feb 2023800
Mar 2023800
Apr 20231500
May 20232401
Jul 2023800
Aug 20232700
Sep 20231100
Nov 2023800
Dec 2023800
Jan 2024200
Feb 2024600
Mar 2024400
Total1160050